Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathy, Demyelinating Disease, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GLDN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GLDN ECD-Fc Fusion Protein (Val28-Thr489) High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed for native glycosylation. Sequence Verified. |
View GLDN Products |
| Gene Delivery | GLDN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer (>1×10⁸ TU/mL) with V5 tag. |
View GLDN Products |
| Benchmark Ab | Anti-GLDN Recombinant Antibody Recombinant positive control for binding and immunofluorescence assays. |
View GLDN Products |
| Validator | GLDN siRNA Set (3 unique sequences) For knockdown verification. Guaranteed >75% mRNA reduction. |
View GLDN Products |
| Related Target: NFASC | Neurofascin (NFASC) Primary interaction partner at the Node of Ranvier; required for GLDN-mediated clustering. |
View NFASC Products |
| Related Target: NRCAM | NrCAM (NRCAM) Co-receptor involved in axoglial junction assembly and paranodal stability. |
View NRCAM Products |
| Related Target: CNTNAP1 | CASPR (CNTNAP1) Paranodal scaffolding protein. Synergistic pathway component for myelin sheath integrity. |
View CNTNAP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Native Glycosylation for Autoantibody Screening | HEK293 Expressed GLDN ECD-Fc ensuring complex human post-translational modifications. |
| Axoglial Junction PPI Assays | High Purity (>95%) strictly verified by SEC-HPLC for accurate SPR/BLI binding kinetics. |
| Cross-species Translational Studies (Cyno/Rat) | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence alignment >92% identity. |
| Node of Ranvier Clustering Assays | Lentivirus-based stable expression in Schwann cells/neurons preserves membrane topology for physiological clustering assays. |
| Lack of Reliable Pathway Controls | Pre-validated NFASC, NRCAM, and CNTNAP1 recombinant proteins available for multiprotein complex assembly. |
| Target Specificity & False Positives | Sequence Verified siRNA and biosimilar control antibodies included for stringent specificity checks. |
Live GLDN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Remyelination Research
- ➤ Latest Resistance & Biomarker Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for targeting axoglial junction proteins like GLDN (Gliomedin) is gaining traction across neuro-immunology, regenerative medicine, and oncology. Initially identified as a critical structural component for the formation of the nodes of Ranvier, GLDN is now emerging as a key biomarker and therapeutic target for peripheral neuropathies (including CIDP and GBS), demyelinating diseases (such as multiple sclerosis), and Charcot-Marie-Tooth disease. Moreover, aberrant GLDN expression is being investigated in specific solid tumors, opening novel avenues for targeted oncology modalities. As next-generation therapies advance, the R&D focus is shifting toward regenerative strategies that stabilize the GLDN-NFASC interaction, employing recombinant Fc-fusion proteins, monoclonal antibodies, gene therapy vectors, and peptide antagonists. First-generation remyelination therapies are reaching Phase I/II, while combinatorial approaches modulating the extracellular matrix-axon interface are on the rise.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking/Activating) | Translational Biotech, Academic Spin-offs | Autoimmune Neuropathies (CIDP, GBS), Peripheral Neuropathy | Epitope Mapping (Need high-purity HEK293-expressed ECD-Fc for native folding) |
| Gene Therapy / AAV | Neuro-regeneration Startups, Novartis, Spark Therapeutics | Peripheral Nerve Injury, Charcot-Marie-Tooth Disease | Functional Rescue Assays (Need sequence-verified Lentivirus for stable cell lines) |
| Recombinant Fc-Fusion | Biogen, Academic Consortia | Multiple Sclerosis (Remyelination) | NFASC186 Binding Assay (Need high-purity ECD-Fc with native disulfide bridges) |
| Targeted Protein Degradation / Small Mol | Early-stage Pharma | Oncology (Emerging Biomarker) | Selectivity & Off-target Screening (Need precision mutant vs WT proteins) |
| Peptide Antagonist | Early-stage Biotechs | Neuropathic Pain | Competitive Binding Assay (Need siRNA controls for off-target verification) |
| Diagnostic Immunoassays | Specialty Diagnostics Cos. | Autoantibody Detection | High Signal-to-Noise ELISA (Need Endotoxin <1EU/ug, >95% purity Antigens) |